Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 1, 2002, Pages 90-99

  Kim, Kyoung Ah ^a,b   Shon, Ji Hong ^a,b   Park, Ji Young ^a,b   Yoon, Young Ran ^a,b   Kim, Min Jung ^a,b   Yun, Doo Hee ^a,b   Kim, Moon Kyung ^a,b   Cha, In June ^a,b   Hyun, Myung Ho ^a,b   Shin, Jae Gook ^a,b  

^a Inje University College of Medicine   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; DRUG METABOLITE; LANSOPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; ENANTIOMER; ENANTIOSELECTIVITY; ENZYME POLYMORPHISM; GENOTYPE; HUMAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ULTRAFILTRATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ALGORITHMS; ANTI-ULCER AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HALF-LIFE; HUMANS; KOREA; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEREOISOMERISM;

EID: 0036338758     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.126176     Document Type: Article

References (31)

1. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells
2. Lansoprazole: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders
3. Oxidative metabolism of lansoprazole by human liver cytochromes P450
4. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status
5. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects
6. CYP2C19 genotype status and intra-gastric pH during dosing with lansoprazole and rabeprazole
7. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin
8. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors - Emphasis on rabeprazole
9. Enantio-selective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects
10. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin
11. Pharmacokinetic differences between lansoprazole enantiomers in rats
12. Effect of the enantiomers of lansoprazole (AG-1749) on (H+/K+)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells
13. Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a trisphenylcarbamoylcellulose-based stationary phase: The effect of the enantiomers of omeprazole on gastric glands
14. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans
15. Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs
16. Frequencies of the detective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
17. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype
18. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population
19. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
20. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population
21. Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography
22. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole
23. Interaction of proton pump inhibitors with cytochrome P450: Consequences for drug interaction
24. Stereo-selective metabolism and inhibitory effects of lansoprazole enantiomers on human liver CYPs
25. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes
26. Distribution
27. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status
28. Interphenotype differences in disposition and effect on gastrin levels of omeprazole suitability of omeprazole as a probe for CYP2C19
29. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype
30. Identification of the human P450 enzymes involved in lansoprazole metabolism
31. Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole - A preliminary study